Cristin-person-ID: 2643
Person

Hoa Thi Tuyet Tran

  • Stilling:
    Cand.med.stipendiater
    ved Avdeling for blodsykdommer ved Oslo universitetssykehus HF

Resultater Resultater

The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro.

Schultz, Nina Haagenrud; Tran, Hoa Thi Tuyet; Bjørnsen, Stine; Henriksson, Carola Elisabeth; Sandset, Per Morten; Holme, Pål Andre. 2017, Research and Practice in Thrombosis and Haemostasis. UIO, AHUS, OUSVitenskapelig artikkel

Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.

Wierda, William G.; Rawstron, Andrew; Cymbalista, Florence; Badoux, Xavier; Rossi, Davide; Brown, Jennifer R.; Egle, Alexander; Abello, Virginia; Cervera Ceballos, Eduardo; Herishanu, Yair mfl.. 2021, Leukemia. UU, AUSTRALIA, TASMC, CANADA, UVSR, DANAFARBER, SINGAPORE, STORBRITAN, LEEDSTH, NTU, FRANKRIKE, MEXICO, UNIVTEXAS, IÜ, COLOMBIA, RH, JAPAN, SVEITS, PMU, AHUSVitenskapelig oversiktsartikkel/review

Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.

Niemann, Carsten; Levin, Mark-David; Dubois, Julie; Kersting, Sabina; Enggaard, Lisbeth; Veldhuis, Gerrit J.; Mous, Rogier; Mellink, Clemens H.M.; Dobber, Johan A.; Poulsen, Christian B. mfl.. 2021, Blood. RUC, UvA, HERLEVHOSP, OUH, KU, TYKS, UMC, UZLEUVEN, AKADEMISKA, RG, RH, AMC, EMC, UMCG, AHUS, NEDERLANDBrev til redaktøren

Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.

Svanberg, Rebecka; Ostrowski, Sisse R.; Nasserinejad, Kazem; Kersting, Sabina; Dobber, Johan A.; Mattson, Mattias; Tran, Hoa Thi Tuyet; Levin, Mark-David; Mous, Rogier; Kater, Arnon P. mfl.. 2020, Leukemia and Lymphoma. UvA, AKADEMISKA, RH, EMC, KU, UMC, AHUS, NEDERLANDVitenskapelig artikkel

Protocol description of the HOVON 141/VISION trial: A prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations.

Levin, Mark-David; Kater, Arnon; Mattsson, Mattias; Kersting, Sabina; Ranti, Juha; Tran, Hoa Thi Tuyet; Nasserinejad, Kazem; Niemann, Carsten. 2020, BMJ Open. Uu, UvA, Ty, RH, EMC, AHUS, NEDERLANDVitenskapelig artikkel
1 - 5 av 15 | Neste | Siste »